Immuneering (IMRX) Corporation announced the formation of its Pancreatic Cancer Advisory Board. The Company’s Pancreatic Cancer Advisory Board includes the following members: Tanios Bekaii-Saab, M.D., Vincent Chung, M.D., FACP, Shubham Pant, M.D., Jordan Berlin, M.D., FASCO.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering granted FDA Fast Track designation for IMM-1-104
- Immuneering Corp. Reports Q3 Loss, Highlights Progress
- Immuneering reports Q3 EPS (49c), consensus (55c)